Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 17/20 | 0.71 |
| ▸ | NPC1 | O15118 | 14/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11783793 | 1.00 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL8526236 | 0.98 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL30582901 | 0.89 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL30582902 | 0.87 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL1713549 | 0.86 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL3549560 | 0.85 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL23965803 | 0.84 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL3216411 | 0.84 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL9571707 | 0.84 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 | |
| SCHEMBL29561851 | 0.84 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021224864-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | disclosed |
| CN-103965186-A | Benzodioxane-benzoxazole (benzothiazole) piperidine derivative and application thereof | JIANGSU NHWA PHARMACEUTICAL CO LTD | 2014-08-06 | — | — | CN | disclosed |
| CN-103965186-A | Benzodioxane-benzoxazole (benzothiazole) piperidine derivative and application thereof | JIANGSU NHWA PHARMACEUTICAL CO LTD | 2014-08-06 | — | — | CN | disclosed |
| US-8759382-B2 | Propargyl-trifluoromethoxy-aminobenzothiazole derivatives, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2014-06-24 | — | — | US | disclosed |
| US-20130172364-A1 | PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-07-04 | — | — | US | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| US-6660751-B1 | Sulfonamide derivatives as 5-HT7 receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-12-09 | — | — | US | disclosed |
| EP-0356385-A2 | New benzazole derivatives, processes for their preparation and pharmaceutical preparations containing such compounds and the use thereof | CIBA-GEIGY AG (CH) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172364-A1 | PROPARGYL-TRIFLUOROMETHOXY-AMINOBENZOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND USE | PARK7, SNCA, PMP22 | RAB9A 1589/4885NPC1 2744/4885SMN1; SMN2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.